Identification of a patient's response to S1P receptor regulation agent medication

Japanese Patent JP6240746

B2

The invention provides a method of assessing the appropriate therapeutic dose of 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid to administer to a patient in need thereof, comprising the steps of:(i) testing whether or not the patient has the poor metabolizer genotype; and(ii) if the patient does not have the poor metaboliser genotype, administering 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, to the patient at the standard therapeutic dose; and(iii) if the patient does have the poor metaboliser genotype, either(a) administering 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, to the patient at a therapeutic dose below that of the standard therapeutic dose; or(b) not administering 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, to the patient.

Borrell, hubert
Ann Gurdin
Jin, Yi
Regan Nukus, Eric
Woofer, microphone

JP2016505716A

November 29, 2017

April 19, 2013

Click for automatic bibliography generation  

Novartis Age

A61K31/397; A61P25/00; A61P37/06; G01N33/50

JP2012513378A

TRENDS in Pharmacological Sciences, 2005, vol.26, No.4, p.196-201

Hiroshi Kobayashi
Norio Omori
Ryo Hoshikawa
Yasuhito Suzuki

Previous Patent: A system and a method of performing a plurality of hypervisors

Next Patent: STRUCTURE OF COLUMN/BEAM CONNECTION PART